Teprotumumab: A Review in Thyroid Eye Disease.

ABSTRACT: Teprotumumab (TEPEZZA^®), a monoclonal antibody that inhibits the insulin-like growth factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment of thyroid eye disease (TED) in the USA. In phase II and III clinical trials in adults with active, moderate-to-severe TED, intravenous teprotumumab significantly improved proptosis response rate and a range of other TED outcomes, including overall response rate, Clinical Activity Score, diplopia and disease-specific quality of life. The clinical benefit of teprotumumab was maintained for up to 51 weeks post-treatment in the majority of patients. Teprotumumab was generally well tolerated; adverse events with the greatest risk difference compared with placebo were muscle spasms, hearing loss and hypergly

SUBMITTER: Nie T 

PROVIDER: S-EPMC9718703 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature